Albendazole-Induced SIRT3 Upregulation Protects Human Leukemia K562 Cells from the Cytotoxicity of MCL1 Suppression

SIRT3, PP2A and TTP protein stability in the presence of TNF‐α on vincristine‐induced apoptosis of leukaemia cells

(2020) Liang‐Jun Wang et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

The anthelmintic drug flubendazole induces cell apoptosis and inhibits NF-κB signaling in esophageal squamous cell carcinoma

(2019) Jiali Tao et al.   OncoTargets and Therapy

Confounding off-target effects of BH3 mimetics at commonly used concentrations: MIM1, UMI-77, and A-1210477

(2019) David J. Mallick et al.   Cell Death & Disease

SIRT3 deacetylase activity confers chemoresistance in AML via regulation of mitochondrial oxidative phosphorylation

(2019) Jiao Ma et al.   BRITISH JOURNAL OF HAEMATOLOGY

Mebendazole as a Candidate for Drug Repurposing in Oncology: An Extensive Review of Current Literature

(2019) Guerini et al.   Cancers

ABT-263-induced MCL1 upregulation depends on autophagy-mediated 4EBP1 downregulation in human leukemia cells

(2018) Yuan-Chin Lee et al.   CANCER LETTERS

Flubendazole elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition

(2018) Eunhye Oh et al.   INTERNATIONAL JOURNAL OF CANCER

Microtubule-Targeting Agents: Strategies To Hijack the Cytoskeleton

(2018) Michel O. Steinmetz et al.   TRENDS IN CELL BIOLOGY

Mebendazole potentiates radiation therapy in triple-negative breast cancer

(2018) Le Zhang et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

The suppressive effect of arsenic trioxide on TET2-FOXP3-Lyn-Akt axis-modulated MCL1 expression induces apoptosis in human leukemia cells

(2018) Ying-Jung Chen et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Non-mitotic effect of albendazole triggers apoptosis of human leukemia cells via SIRT3/ROS/p38 MAPK/TTP axis-mediated TNF-α upregulation

(2018) Liang-Jun Wang et al.   BIOCHEMICAL PHARMACOLOGY

BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines

(2018) Delphine Merino et al.   CANCER CELL

Microtubule destabilising agents: far more than just antimitotic anticancer drugs

(2016) Darcy Bates et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Albendazole as a promising molecule for tumor control

(2016) L.S.E.P.W. Castro et al.   Redox Biology

Activation of SIRT3 by resveratrol ameliorates cardiac fibrosis and improves cardiac function via the TGF-β/Smad3 pathway

(2015) Tongshuai Chen et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Antihelminthic benzimidazoles potentiate navitoclax (ABT-263) activity by inducing Noxa-dependent apoptosis in non-small cell lung cancer (NSCLC) cell lines

(2015) Lloyd T Lam et al.   Cancer Cell International

Imidazoles and Benzimidazoles as Tubulin-Modulators for Anti-Cancer Therapy

(2015) Fernando Torres et al.   CURRENT MEDICINAL CHEMISTRY

Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)

(2015) J D Leverson et al.   Cell Death & Disease

The NOXA–MCL1–BIM axis defines lifespan on extended mitotic arrest

(2015) Manuel D. Haschka et al.   Nature Communications

Regulation of Mcl-1 by constitutive activation of NF-kappaB contributes to cell viability in human esophageal squamous cell carcinoma cells

(2014) Haidan Liu et al.   BMC CANCER

Caspase-dependent Mcl-1 cleavage and effect of Mcl-1 phosphorylation in ABT-737-induced apoptosis in human acute lymphoblastic leukemia cell lines

(2014) YongKu Ryu et al.   EXPERIMENTAL BIOLOGY AND MEDICINE

The Bcl-2/xL inhibitor ABT-263 increases the stability of Mcl-1 mRNA and protein in hepatocellular carcinoma cells

(2014) Bin Wang et al.   Molecular Cancer

Targeting Microtubules by Natural Agents for Cancer Therapy

(2014) E. Mukhtar et al.   MOLECULAR CANCER THERAPEUTICS

Mcl-1 Ubiquitination: Unique Regulation of an Essential Survival Protein

(2014) Barbara Mojsa et al.   Cells

SIRT3, a pivotal actor in mitochondrial functions: metabolism, cell death and aging

(2012) Albert Giralt et al.   BIOCHEMICAL JOURNAL

Suppression of Akt/Foxp3-mediated miR-183 expression blocks Sp1-mediated ADAM17 expression and TNFα-mediated NFκB activation in piceatannol-treated human leukemia U937 cells

(2012) Wen-Hsin Liu et al.   BIOCHEMICAL PHARMACOLOGY

Tumour suppressor SIRT3 deacetylates and activates manganese superoxide dismutase to scavenge ROS

(2011) Yaohui Chen et al.   EMBO REPORTS

Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7

(2011) Ingrid E. Wertz et al.   NATURE

Mitosis is not a key target of microtubule agents in patient tumors

(2011) Edina Komlodi-Pasztor et al.   Nature Reviews Clinical Oncology

The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma

(2010) P. A. Spagnuolo et al.   BLOOD

Mcl-1; the molecular regulation of protein function

(2010) Luke W. Thomas et al.   FEBS LETTERS

Microtubule-binding agents: a dynamic field of cancer therapeutics

(2010) Charles Dumontet et al.   NATURE REVIEWS DRUG DISCOVERY

SIRT3 Is a Stress-Responsive Deacetylase in Cardiomyocytes That Protects Cells from Stress-Mediated Cell Death by Deacetylation of Ku70

(2008) N. R. Sundaresan et al.   MOLECULAR AND CELLULAR BIOLOGY